Research Peptide Guides
Independent guides on research peptide sourcing, COA verification, pricing, and compound stacks. No paid placements.
Are Research Peptides Legal in the US? 2026 Guide
Plain-English breakdown of FDA categories, the research-use-only framework, what changed in 2021–2026, and the current enforcement reality.
Read guide →Research Compounds for Beginners
Which compounds have the most evidence, what questions to ask, and how to evaluate sources responsibly.
Read guide →Best Peptide Suppliers 2026
Independent review of 60+ US vendors by COA quality, price-per-mg, and stock reliability.
Read guide →Best Research Peptides for Fat Loss 2026
Evidence-ranked overview — GLP-1s with human trial data, AOD-9604 Phase 2 results, and GH secretagogues for indirect fat metabolism effects.
Read guide →Best Research Peptides for Longevity and Anti-Aging 2026
Evidence-ranked guide to Epithalon, MOTS-C, SS-31, FOXO4-DRI, and Thymosin Alpha-1 — compounds studied for telomere biology, mitochondrial health, senescent cell clearance, and immunosenescence.
Read guide →Best Research Peptides for Muscle Recovery 2026
BPC-157, TB-500, IGF-1 LR3, and GH secretagogues ranked by evidence strength for muscle repair and soft tissue recovery.
Read guide →BPC-157 Dosage: What Animal Research Suggests in 2026
Doses used in published BPC-157 studies, BSA-adjusted human estimates, routes compared, and why purity matters for dosing accuracy.
Read guide →BPC-157 + TB-500 Stack
Mechanistic rationale for stacking, with price comparison across 3P-verified suppliers.
Read guide →What Is a Certificate of Analysis?
What a real COA contains, how to verify it, and red flags to watch for.
Read guide →How to Compare Peptide Prices
Price-per-mg explained, why prices vary, and a step-by-step tool walkthrough.
Read guide →The Case AGAINST 5-Amino-1MQ
Primarily in vitro and rodent data. No human trials, unknown off-target effects, limited long-term safety data.
Read guide →The Case AGAINST AOD-9604
Phase 3 obesity trials failed — FDA approval never granted. Limited evidence beyond fat cell lipolysis.
Read guide →The Case AGAINST ARA-290 (Cibinetide)
Stalled development program despite Phase II success a decade ago, no regulatory approval, narrow indication evidence base, and unknown long-term safety of chronic IRR agonism.
Read guide →The Case AGAINST BPC-157
No human RCTs, FDA non-approval, unknown long-term safety, and market quality risks.
Read guide →The Case AGAINST CagriSema Stack
Still in Phase 3, not approved. Additive GI side effects and combined dosing complexity.
Read guide →The Case AGAINST Cagrilintide
Not yet FDA-approved, Phase 3 in progress. Additive GI side effects when stacked with semaglutide.
Read guide →The Case AGAINST CJC-1295
Continuous GH elevation vs physiological pulsatile release. Acromegaly risk and insulin resistance concerns.
Read guide →The Case AGAINST CJC-1295/Ipamorelin Stack
No FDA approval for either compound. Combined GH elevation carries acromegaly and insulin resistance risks.
Read guide →The Case AGAINST DSIP
Unknown receptor, Monnier findings never robustly replicated, BBB penetration questioned, very thin human data.
Read guide →The Case AGAINST Epithalon
Single Russian research group, no Western replication. Telomerase-cancer paradox. No human RCTs.
Read guide →The Case AGAINST FOXO4-DRI
Single landmark study with no human follow-up. Senescent cells have beneficial roles. Zero human safety data.
Read guide →The Case AGAINST GHK-Cu
Copper toxicity risks, systemic administration unknowns, and topical-vs-injectable evidence gaps.
Read guide →The Case AGAINST GHRP-2
Strongest cortisol and prolactin elevation, appetite stimulation, water retention, no FDA approval.
Read guide →The Case AGAINST GHRP-6
Significant appetite stimulation, cortisol and prolactin elevation, less selective than newer GHRPs.
Read guide →The Case AGAINST GLOW Peptide Blend
Proprietary blend with unknown exact ratios. No combination-specific evidence.
Read guide →The Case AGAINST Retatrutide + Tirzepatide Stack
Purely speculative — no clinical data. Redundant receptor activity, compounded side effects, highest-risk stack.
Read guide →The Case AGAINST Glutathione
Oral bioavailability is negligible. Injectable use raises safety questions. Antioxidant research is complex.
Read guide →The Case AGAINST HCG
Estrogen elevation via aromatization, gynecomastia risk, receptor desensitization with chronic use, and a significant quality gap between pharmaceutical and research-grade glycoprotein hormones.
Read guide →The Case AGAINST Hexarelin
Rapid desensitization with repeated use, cortisol and prolactin elevation, cardioprotective data is preclinical.
Read guide →The Case AGAINST IGF-1 LR3
Hypoglycemia risk, PI3K/mTOR cancer promotion concern, acromegalic effects at high doses, WADA prohibition.
Read guide →The Case AGAINST Ipamorelin
No FDA approval, GH axis suppression risk, unknown long-term effects.
Read guide →The Case AGAINST Kisspeptin
Very short half-life requiring near-continuous infusion. Limited data outside IVF/diagnostics.
Read guide →The Case AGAINST KLOW Peptide Blend
Proprietary blend with unknown ratios. No combination clinical data. Recovery claims based on individual compound evidence only.
Read guide →The Case AGAINST KPV
No human clinical data — evidence is cell culture and rodent only. Unknown optimal dosing.
Read guide →The Case AGAINST LL-37 (Cathelicidin)
Pro-inflammatory dual role, autoimmune amplification risk, cytotoxicity at high concentrations, cancer promotion data, and systemic human safety data is absent.
Read guide →The Case AGAINST Melanotan I
Scenesse approved only for EPP (rare disease). Research-grade is not Scenesse.
Read guide →The Case AGAINST Melanotan II
Not FDA-approved, naevi darkening and melanoma concern, banned in UK/Australia/Canada.
Read guide →The Case AGAINST MOTS-C
Minimal human evidence, unknowns around dosing, and real risk for early adopters.
Read guide →The Case AGAINST NAD+
Poor oral bioavailability, IV administration discomfort, conflicting trial results, sirtuin-longevity unproven.
Read guide →The Case AGAINST Oxytocin
Replication failures in the trust literature, context-dependent pro-anxiety effects, receptor downregulation with chronic use, and an uncharacterized injectable pharmacokinetic profile.
Read guide →The Case AGAINST Pinealon
Almost entirely a single Russian research group. No peer-reviewed RCTs in Western journals.
Read guide →The Case AGAINST PT-141
Approved only for premenopausal women with HSDD. Nausea in ~40%, transient hypertension, male use off-label.
Read guide →The Case AGAINST Retatrutide
No FDA approval, Phase 3 still underway, glucagon receptor unknowns, and no long-term safety data.
Read guide →The Case AGAINST Selank
Exclusively Russian research, no Western RCT replication. Short half-life, intranasal bioavailability variability.
Read guide →The Case AGAINST Selank + Semax Stack
Zero Western RCT data for either compound individually, let alone combined. Combination effects unstudied.
Read guide →The Case AGAINST Semaglutide
GI side effects, thyroid concerns, muscle loss, rebound weight, and sourcing quality risks.
Read guide →The Case AGAINST Semax
Russia-centric evidence base, no Western RCT replication. HPA axis uncertainty.
Read guide →The Case AGAINST Sermorelin
FDA approval withdrawn (manufacturer decision), short half-life, adult use extrapolated from pediatric data.
Read guide →The Case AGAINST Setmelanotide
Approved conditions are genuinely rare. Hyperpigmentation in ~90%, daily injection only.
Read guide →The Case AGAINST SNAP-8
Primarily cosmetic/topical with modest efficacy vs botulinum toxin. Mostly manufacturer-funded studies.
Read guide →The Case AGAINST SS-31 (Elamipretide)
EMBARK Phase 3 trial failed in 2021. Stealth BioTherapeutics bankrupt. Development discontinued.
Read guide →The Case AGAINST TB-500
No human RCTs, WADA prohibition, theoretical tumor promotion concern, and variable supply quality.
Read guide →The Case AGAINST Teriparatide
Black box warning for osteosarcoma, approved only for osteoporosis, 2-year maximum treatment duration.
Read guide →The Case AGAINST Tesamorelin + Ipamorelin Stack
Tesamorelin approval does not extend to this combination. No stack-specific human trial data.
Read guide →The Case AGAINST Tesamorlin
Approved only for HIV lipodystrophy — all other uses are off-label. Glucose metabolism effects.
Read guide →The Case AGAINST Thymosin Alpha-1
No FDA approval despite international approvals. Autoimmune stimulation risk, injection-only delivery.
Read guide →The Case AGAINST Tirzepatide
Side effect profile, rebound risk, muscle loss concerns, and unregulated sourcing problems.
Read guide →The Case AGAINST VIP
1–2 minute half-life severely limits research utility. Hypotension risk, delivery constraints, no FDA approval.
Read guide →The Case AGAINST the Wolverine Stack
No combination-specific clinical data. Additive side effect risk, sourcing two compounds doubles QC burden.
Read guide →GLP-1 Peptide Comparison 2026: Semaglutide vs Tirzepatide vs Retatrutide
Mechanism, efficacy data, safety profile, and pricing compared across the three main GLP-1-class research compounds.
Read guide →How to Choose a Supplier
5 criteria that separate legitimate vendors from risky ones — COA, pricing, transparency, red flags.
Read guide →Injectable vs Oral vs Nasal
Route of administration and bioavailability for SubQ injection, oral, and nasal research compounds.
Read guide →Ipamorelin vs Sermorelin: GH Secretagogue Comparison 2026
Mechanism, human data, half-life, and practical differences between the two most common GH-stimulating research compounds.
Read guide →How to Reconstitute and Store Research Peptides
Bacteriostatic water vs sterile water, dilution ratios, storage temps, and common mistakes that degrade compounds.
Read guide →The Case FOR 5-Amino-1MQ
NNMT inhibitor that shifts cellular metabolism toward fat oxidation. Novel mechanism with adipogenesis data.
Read guide →The Case FOR AOD-9604
C-terminal fragment of hGH targeting fat metabolism without IGF-1 elevation. What Phase 2 data showed.
Read guide →The Case FOR ARA-290 (Cibinetide)
IRR-selective EPO derivative with Phase II human data showing nerve fiber regeneration in sarcoidosis neuropathy. Tissue-protective without EPO's erythropoietic risks.
Read guide →The Case FOR BPC-157
What the preclinical research actually shows — mechanisms, strongest applications, honest framing.
Read guide →The Case FOR CagriSema (Cagrilintide + Semaglutide)
Amylin + GLP-1 dual mechanism showing ~15% weight loss in Phase 2. REDEFINE Phase 3 rationale.
Read guide →The Case FOR Cagrilintide
Amylin analogue from Novo Nordisk showing ~15% weight loss in Phase 2. Combined with semaglutide in REDEFINE.
Read guide →The Case FOR CJC-1295
GHRH analogue with DAC technology extending half-life to days. Sustained GH and IGF-1 elevation in human research.
Read guide →The Case FOR CJC-1295 / Ipamorelin (No DAC)
Most studied GH optimization stack — GHRH + GHRP synergy documented in GH secretion studies.
Read guide →The Case FOR DSIP
Endogenous nonapeptide with delta-wave sleep promotion and GH/LH modulation data.
Read guide →The Case FOR Epithalon
Khavinson tetrapeptide with telomerase activation data in human fibroblasts and lifespan extension in animals.
Read guide →The Case FOR FOXO4-DRI
Senolytic peptide that disrupts FOXO4-p53 interaction. The Baar et al. 2017 Nature Medicine mouse study.
Read guide →The Case FOR GHK-Cu
50+ years of research — wound healing, collagen synthesis, and anti-inflammatory signaling.
Read guide →The Case FOR GHRP-2
More potent GH release than GHRP-6. What the comparative secretagogue data shows.
Read guide →The Case FOR GHRP-6
First synthetic GHRP. What 30+ years of data shows on GH release and synergy with GHRH analogues.
Read guide →The Case FOR GLOW Peptide Blend
Skin and beauty focused blend combining GHK-Cu, BPC-157, and other skin-relevant peptides.
Read guide →The Case FOR Retatrutide + Tirzepatide Stack
Mechanistic rationale for combining a triple agonist with a dual agonist — receptor overlap and additive effects.
Read guide →The Case FOR Glutathione
Master antioxidant tripeptide. What IV/injectable glutathione research shows for oxidative stress.
Read guide →The Case FOR HCG
FDA-approved LH mimetic with the strongest clinical evidence base of any compound in this space. Proven testosterone stimulation, fertility support, and testicular preservation data.
Read guide →The Case FOR Hexarelin
GHRP with unique cardioprotective data beyond GH secretion. What the CD36 receptor cardiac research shows.
Read guide →The Case FOR IGF-1 LR3
13x longer half-life than native IGF-1. Anabolic and tissue repair research — satellite cell activation.
Read guide →The Case FOR Ipamorelin
Selective GH secretagogue with minimal cortisol/prolactin side effects. What the GH pulse data shows.
Read guide →The Case FOR Kisspeptin
GnRH pulse trigger with genuine human trial data. IVF oocyte maturation studies and fertility research.
Read guide →The Case FOR KLOW Peptide Blend
Recovery and joint focused blend combining BPC-157, TB-500, and other healing peptides.
Read guide →The Case FOR KPV
Alpha-MSH C-terminal tripeptide with NF-kB anti-inflammatory mechanism. IBD preclinical data.
Read guide →The Case FOR LL-37 (Cathelicidin)
Human antimicrobial peptide with broad-spectrum activity, anti-biofilm properties, wound healing data, and a Phase II clinical trial in venous leg ulcers.
Read guide →The Case FOR Melanotan I (MT-1)
MC1R-selective agonist FDA-approved as Scenesse. The cleanest melanocortin evidence base.
Read guide →The Case FOR Melanotan II
UV-independent tanning and sexual function research data. What early human trials actually showed.
Read guide →The Case FOR MOTS-C
Mitochondria-derived peptide with emerging data on insulin sensitivity and longevity signaling.
Read guide →The Case FOR NAD+
Mitochondrial cofactor central to energy metabolism. Injectable NAD+ research vs oral precursors.
Read guide →The Case FOR Oxytocin
Endogenous neuropeptide with FDA-approved obstetric use. Prosocial and anxiolytic effects replicated across hundreds of human studies, plus anti-inflammatory preclinical data.
Read guide →The Case FOR Pinealon
Khavinson tripeptide bioregulator. Russian gerontology research on neuroprotection and melatonin regulation.
Read guide →The Case FOR PT-141
FDA-approved as Vyleesi for HSDD in women. Central MC4R mechanism vs peripheral PDE5 approach.
Read guide →The Case FOR Retatrutide
Triple GLP-1/GIP/glucagon agonist with 24.2% mean weight loss in Phase 2. What the NEJM data shows.
Read guide →The Case FOR Selank
Tuftsin-derived heptapeptide registered as anxiolytic in Russia. GABA-independent mechanism, BDNF upregulation.
Read guide →The Case FOR Selank + Semax Stack
Complementary Russian-approved nootropic stack — anxiolytic Selank paired with cognitive Semax.
Read guide →The Case FOR Semaglutide
GLP-1 mechanisms, weight loss trial data, cardiovascular outcomes — what the science supports.
Read guide →The Case FOR Semax
ACTH(4-7)PGP analogue registered as nootropic in Russia. BDNF and NGF upregulation, stroke model data.
Read guide →The Case FOR Sermorelin
GHRH(1-29) analogue that preserves pulsatile GH release. Formerly FDA-approved, strong evidence base.
Read guide →The Case FOR Setmelanotide
FDA-approved MC4R agonist for rare genetic obesity. ~80% response rate in approved populations.
Read guide →The Case FOR SNAP-8
Acetyl octapeptide-3 targeting SNARE complex to reduce expression line depth. Topical anti-wrinkle research.
Read guide →The Case FOR SS-31 (Elamipretide)
Mitochondria-targeting peptide that binds cardiolipin. Independent replication of ischemia-reperfusion protection.
Read guide →The Case FOR TB-500
Thymosin Beta-4 fragment with actin-sequestering mechanism. What the preclinical evidence shows.
Read guide →The Case FOR Teriparatide
PTH(1-34) FDA-approved as Forteo for osteoporosis. Level I clinical evidence for anabolic bone building.
Read guide →The Case FOR Tesamorelin + Ipamorelin Stack
Combines strongest-evidenced GHRH analogue with a selective GHRP. GHRH + GHRP synergy for GH pulse amplitude.
Read guide →The Case FOR Tesamorelin
The only GHRH analogue with FDA approval. What the Phase 3 clinical trial data demonstrated.
Read guide →The Case FOR Thymosin Alpha-1
Approved as Zadaxin in 35+ countries for immune modulation. TLR signaling and T-cell maturation data.
Read guide →The Case FOR Tirzepatide
Dual GIP/GLP-1 agonist mechanism. What the SURMOUNT and SURPASS trials actually showed.
Read guide →The Case FOR VIP
Vasoactive Intestinal Peptide with VPAC1/2 receptor pharmacology. PAH research and NF-kB anti-inflammatory signaling.
Read guide →The Case FOR BPC-157 + TB-500 (Wolverine Stack)
Most popular healing/recovery stack — complementary angiogenesis and actin-sequestering mechanisms.
Read guide →Semaglutide Dosage: What the Clinical Trials Show in 2026
STEP trial dose escalation schedules, weight loss by dose, subcutaneous vs oral comparison, and why research-grade purity matters for dosing accuracy.
Read guide →What Is a COA for Peptides?
Third-party vs in-house testing explained. Red flags to watch, and how to verify a COA.
Read guide →